Results 151 to 160 of about 22,516 (228)

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts. [PDF]

Cancer Discov
Shi W, Xu P, Gu Q, Fan Z, Liang X, Wang Y, Zhao Y, Meng C, Leo J, Kim JJ, Teng H, Zhang J, Chen F, Chen Y, Navin NE, Zhao D.   +15 more
europepmc   +1 more source

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC. [PDF]

Prostate
Hashimoto K, Izumi K, Shima T, Kato Y, Mita K, Okamura T, Inoue S, Tatarano S, Tanaka N, Kawai N, Kamiyama M, Chikazawa I, Hoshi S, Fukagai T, Shigehara K, Takahara S, Mizokami A.   +16 more
europepmc   +1 more source

Editorial Comment on Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa. [PDF]

Int J Urol
Arai S.
europepmc   +1 more source

Integrative omics identify NID2 as a therapeutic target linking depression and colorectal cancer in humans. [PDF]

iScience
Huang L, Wang J, Tian H, Wang W, Nie Z, Cui X, Zhang L, Jin Y, Ding Y, Liu Z, Yu H, Wu L.   +11 more
europepmc   +1 more source

In silico high-throughput screening system for INMT activators in prostate cancer therapy. [PDF]

Front Pharmacol
Zheng H, Cao S, Kong Z, Xin P, Bi J, Wang J.   +5 more
europepmc   +1 more source

Editorial: Advances in combined modality treatments for prostate cancer. [PDF]

Front Surg
Sun F.
europepmc   +1 more source

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223. [PDF]

EJNMMI Rep
Fukushima Y, Kimura G, Akatsuka J, Honda Y, Nakaoka Y, Hayashi H, Kumita S.   +6 more
europepmc   +1 more source

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. [PDF]

Front Oncol
Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L.
europepmc   +1 more source

SETDB1-mediated repression of RhoB promotes EMT and metastatic progression in prostate cancer. [PDF]

Oncogene
Cong H, Seilani F, Goettl R, He D, Liu J, Wang C, Liu X, Wang R, Fong KW.   +8 more
europepmc   +1 more source

Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry. [PDF]

Support Care Cancer
Solberg A, Grydeland M, Nilsen TS, Storås AH, Davis ID, Greaves N, Anderson S, Fay AP, Chi KN, Enting D, McDermott R, Badal S, Waihenya CG, Popoola A, Lazarus JM, Mateo J, Bjartell A, Omlin A, Odedina F, Ragin C, Mucci LA, Russnes KM, IRONMAN investigators.   +22 more
europepmc   +1 more source